Rutgers New Jersey Medical School is one of nearly 80 sites in the United States that will enroll participants in a new study to evaluate whether tecovirimat is effective in treating human monkeypox.  The randomized, placebo-controlled, double-blind trial has been designed to test the safety and efficacy of tecovirimat in the treatment of monkeypox. The Study of Tecovirimat for Human Monkeypox virus (STOMP) has been designed to learn as much as possible from a broad population of people with monkeypox. To read the full story.